Predictive value of ovarian hormone-producing function assessment in poor responders undergoing assisted reproductive technologies

Cover Page


Cite item

Full Text

Abstract

Hypothesis/aims of study. The management of poor responders to ovarian stimulation for in vitro fertilization (IVF) has always been a challenge. It is difficult for both doctors and patients to make decision to proceed to oocyte donation or abandon fertility treatment. More predictors of successful IVF treatment in poor responders are needed. The aim of this study was to assess hormonal ovarian function in poor responders undergoing ovarian stimulation and to identify predictors of the chance of clinical pregnancy after IVF cycle.

Study design, materials and methods. The study included 45 infertile patients undergoing ovarian stimulation with poor ovarian response according to the Bologna criteria. All patients underwent standard IVF or IVF/ICSI protocol using gonadotropin releasing hormone antagonists. Letrozole (5 mg/day) was administered during the first 5 days of stimulation in standard antagonist FSH/hMG protocol to 13 of the patients included in the study, with standard antagonist FSH/hMG protocol being only administered to other 32 patients. Serum and follicular fluid were collected at the time of follicle aspiration, and the concentrations of total testosterone, estradiol and androstenedione were determined.

Results. Follicular fluid concentrations of testosterone and androstenedione were higher and serum estradiol level was lower in the letrozole group. The serum concentrations of testosterone and androstenedione were comparable in both groups, while the serum estradiol/testosterone ratio was lower in the letrozole group. The threshold level of estradiol/testosterone ratio × 1000 on the day of oocyte retrieval above which pregnancy and implantation rates were increased was 1532.68 (odds ratio — 7.0 (95% CI 1.39–35.35), р = 0.02).

Conclusion. Evaluating of the serum estradiol / testosterone ratio has been shown to determine aromatase activity of ovarian preovulatory follicles and to predict IVF outcome in poor responders undergoing assisted reproductive technology.

About the authors

Alexandra I. Merkulova

Saint Petersburg State University

Author for correspondence.
Email: merkulova.alexandra@gmail.com
ORCID iD: 0000-0001-5555-2425
SPIN-code: 5109-0816

MD, Postgraduate student. The Department of Obstetrics, Gynecology, and Reproductive Sciences, Medical Faculty

Russian Federation, Saint Petersburg

Lyailya Kh. Dzhemlikhanova

Saint Petersburg State University; The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: dzhemlikhanova_l@mail.ru
ORCID iD: 0000-0001-6842-4430
SPIN-code: 1691-6559

MD, PhD, Associate Professor. The Department of Obstetrics, Gynecology, and Reproductive Sciences, Medical Faculty; the Department of Assisted Reproductive Technologies

Russian Federation, Saint Petersburg

Dariko A. Niauri

Saint Petersburg State University; The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: d.niauri@mail.ru
ORCID iD: 0000-0003-1556-248X
SPIN-code: 4384-9785

MD, PhD, DSci (Medicine), Professor, the Head of the Department of Obstetrics, Gynecology, and Reproductive Sciences, Medical Faculty; Leading Researcher. The Gynecological Department with the Operation Unit

Russian Federation, Saint Petersburg

Alexander M. Gzgzyan

Saint Petersburg State University; The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: agzgzyan@mail.ru
ORCID iD: 0000-0003-3917-9493
SPIN-code: 6412-4801

MD, PhD, DSci (Medicine), Professor. The Department of Obstetrics, Gynecology, and Reproductive Sciences, Medical Faculty; the Head of the Department of Assisted Reproductive Technologies

Russian Federation, Saint Petersburg

Igor Yu. Kogan

Saint Petersburg State University; The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: ikogan@mail.ru
ORCID iD: 0000-0002-7351-6900
SPIN-code: 6572-6450

MD, PhD, DSci (Medicine), Professor, Corresponding Member of RAS. The Department of Obstetrics, Gynecology, and Reproductive Sciences, Medical Faculty; Director

Russian Federation, Saint Petersburg

Inna O. Krikheli

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: ikrikhely@gmail.com
ORCID iD: 0000-0002-5439-1727
SPIN-code: 7356-6189

MD, PhD, Senior Researcher

Russian Federation, Saint Petersburg

Natalya I. Tapilskaya

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott; Saint Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation

Email: tapnatalia@yandex.ru
ORCID iD: 0000-0001-5309-0087
SPIN-code: 3605-0413

MD, PhD, DSci (Medicine), Professor, Leading Researcher; Professor. The Department of Obstetrics and Gynecology with the Course of Pediatric and Adolescent Gynecology

Russian Federation, Saint Petersburg

Natalia N. Tkachenko

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: liberin@mail.ru
ORCID iD: 0000-0001-6189-3488
SPIN-code: 9633-6701

PhD, the Head of the Laboratory of Endocrinology

Russian Federation, Saint Petersburg

Irina D. Mekina

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: iagmail@ott.ru
ORCID iD: 0000-0002-0813-5845
SPIN-code: 4682-8590

PhD, Senior Researcher. The Department of Assisted Reproductive Technologies

Russian Federation, Saint Petersburg

Elena A. Lesik

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: iagmail@ott.ru

PhD, Senior Researcher. The Department of Assisted Reproductive Technologies

Russian Federation, Saint Petersburg

Evgenia M. Komarova

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: iagmail@ott.ru
ORCID iD: 0000-0002-9988-9879
SPIN-code: 1056-7821

PhD, Researcher. The Department of Assisted Reproductive Technologies

Russian Federation, Saint Petersburg

References

  1. Broer SL, van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19(1):26-36. https://doi.org/10.1093/humupd/dms041.
  2. Vaegter KK, Lakic TG, Olovsson M, et al. Which factors are most predictive for live birth after in vitro fertilization and intracytoplasmic sperm injection (IVF/ICSI) treatments? Analysis of 100 prospectively recorded variables in 8,400 IVF/ICSI single-embryo transfers. Fertil Steril. 2017;107(3):641-648.e2. https://doi.org/10.1016/j.fertnstert.2016.12.005.
  3. Tal R, Tal O, Seifer BJ, Seifer DB. Antimullerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertil Steril. 2015;103(1):119-130;e113. https://doi.org/10.1016/j.fertnstert.2014.09.041.
  4. Chai J, Lee VC, Yeung TW, et al. Live birth and cumulative live birth rates in expected poor ovarian responders defined by the Bologna criteria following IVF/ICSI treatment. PLoS One. 2015;10(3):e0119149. https://doi.org/10.1371/journal.pone.0119149.
  5. Polyzos NP, Nwoye M, Corona R, et al. Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF/ICSI. Reprod Biomed Online. 2014;28(4):469-474. https://doi.org/10.1016/j.rbmo.2013.11.010.
  6. Назаренко Т.А., Краснопольская К.В. «Бедный ответ». Тактика ведения пациенток со сниженной реакцией на стимуляцию гонадотропинами в программах ЭКО. – М.: МЕДпресс-информ, 2012. [Nazarenko TA, Krasnopol’skaya KV. “Bednyy otvetˮ. Taktika vedeniya patsientok so snizhennoy reaktsiey na stimulyaciyu gonadotropinami v programmakh EKO. Moscow: MEDpress-inform; 2012. (In Russ.)]
  7. Jeve YB, Bhandari HM. Effective treatment protocol for poor ovarian response: A systematic review and meta-analysis. J Hum Reprod Sci. 2016;9(2):70-81. https://doi.org/10.4103/0974-1208.183515.
  8. Wiggins DA, Main E. Outcomes of pregnancies achieved by donor egg in vitro fertilization – a comparison with standard in vitro fertilization pregnancies. Am J Obstet Gynecol. 2005;192(6):2002-2006; discussion 2006-2008. https://doi.org/10.1016/j.ajog.2005.02.059.
  9. De Geyter C, Calhaz-Jorge C, Kupka MS, et al. ART in Europe, 2014: results generated from European registries by ESHRE: The European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod. 2018;33(9):1586-1601. https://doi.org/10.1093/humrep/dey242.
  10. Zhang Y, Xu Y, Xue Q, et al. Discordance between antral follicle counts and anti-Mullerian hormone levels in women undergoing in vitro fertilization. Reprod Biol Endocrinol. 2019;17(1):51. https://doi.org/10.1186/s12958-019-0497-4.
  11. Hennet ML, Combelles CM. The antral follicle: a microenvironment for oocyte differentiation. Int J Dev Biol. 2012;56(10-12):819-831. https://doi.org/10.1387/ijdb.120133cc.
  12. Tiwari M, Prasad S, Tripathi A, et al. Apoptosis in mammalian oocytes: a review. Apoptosis. 2015;20(8):1019-1025. https://doi.org/10.1007/s10495-015-1136-y.
  13. Assou S, Haouzi D, De Vos J, Hamamah S. Human cumulus cells as biomarkers for embryo and pregnancy outcomes. Mol Hum Reprod. 2010;16(8):531-538. https://doi.org/10.1093/molehr/gaq032.
  14. Uyar A, Torrealday S, Seli E. Cumulus and granulosa cell markers of oocyte and embryo quality. Fertil Steril. 2013;99(4):979-997. https://doi.org/10.1016/j.fertnstert. 2013.01.129.
  15. Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616-1624. https://doi.org/10.1093/humrep/der092.
  16. Патент РФ на изобретение № 2619345/15.05.2017. Бюл. № 14. Потин В.В., Тарасова М.А., Ярмолинская М.И., и др. Способ оценки ароматазной активности антральных фолликулов яичников. [Patent RUS No. 2619345/15.05.2017. Byul. No. 14. Potin VV, Tarasova MA, Yarmolinskaya MI, et al. Sposob otsenki aromataznoy aktivnosti antral’nykh follikulov yaichnikov. (In Russ.)]
  17. Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92(2):405-413. https://doi.org/10.1210/jc.2006-1864.
  18. Патент РФ на изобретение № 2481587/10.05.2013. Бюл. № 13. Потин В.В., Тарасова М.А., Ярмолинская М.И., и др. Способ оценки ароматазной активности. [Patent RUS No. 2481587/10.05.2013. Byul. No. 13. Potin VV, Tarasova MA, Yarmolinskaya MI, et al. Sposob otsenki aromataznoy aktivnosti. (In Russ.)]
  19. Патент РФ на изобретение № 2549491/27.04.2015. Бюл. № 12. Потин В.В., Тарасова М.А., Ярмолинская М.И., и др. Способ оценки овариальной ароматазной активности. [Patent RUS No. 2549491/27.04.2015. Byul. No. 12. Potin VV, Tarasova MA, Yarmolinskaya MI, et al. Sposob otsenki ovarial’noy aromataznoy aktivnosti. (In Russ.)]
  20. Мишарина Е.В. Содержание эстрона, андростендиона и β-эндорфина в крови женщин с ожирением и нарушением репродуктивной функции: дис. … канд. мед. наук. – СПб., 1993. [Misharina YV. Soderzhanie estrona, androstendiona i β-endorfina v krovi zhenshchin s ozhireniem i narusheniem reproduktivnoy funktsii. [dissertation] Saint Petersburg; 1993. (In Russ.)]
  21. Sasano H, Edwards DP, Anderson TJ, et al. Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report. J Steroid Biochem Mol Biol. 2003;86(3-5):239-244. https://doi.org/10.1016/s0960-0760(03)00363-7.
  22. Kinoshita T, Honma S, Shibata Y, et al. An innovative LC-MS/MS-based method for determining CYP 17 and CYP 19 activity in the adipose tissue of pre- and postmenopausal and ovariectomized women using 13C-labeled steroid substrates. J Clin Endocrinol Metab. 2014;99(4):1339-1347. https://doi.org/10.1210/jc.2013-3715.
  23. Simpson ER, Merrill JC, Hollub AJ, et al. Regulation of estrogen biosynthesis by human adipose cells. Endocr Rev. 1989;10(2):136-148. https://doi.org/10.1210/edrv-10-2-136.
  24. Shaw ND, Srouji SS, Welt CK, et al. Compensatory increase in ovarian aromatase in older regularly cycling women. J Clin Endocrinol Metab. 2015;100(9):3539-3547. https://doi.org/10.1210/JC.2015-2191.
  25. Joo BS, Park SH, An BM, et al. Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of in vitro fertilization in a concentration-dependent manner. Fertil Steril. 2010;93(2):442-446. https://doi.org/10.1016/j.fertnstert.2009.02.066.
  26. Mitwally MF, Bhakoo HS, Crickard K, et al. Estradiol production during controlled ovarian hyperstimulation correlates with treatment outcome in women undergoing in vitro fertilization-embryo transfer. Fertil Steril. 2006;86(3):588-596. https://doi.org/10.1016/j.fertnstert. 2006.02.086.
  27. Steward RG, Zhang CE, Chen C, et al. High peak estradiol (E2) predicts higher miscarriage (MC) and lower live birth (LB) rates in high-responders triggered with a gonadotropin releasing hormone agonist (GnRHa) in IVF/ICSI cycles. Fertil Steril. 2013;100(3):S139-S140. https://doi.org/10.1016/ j.fertnstert.2013.07.1571.
  28. Guo J, Zhang Q, Li Y, et al. Predictive value of androgens and multivariate model for poor ovarian response. Reprod Biomed Online. 2014;28(6):723-732. https://doi.org/10.1016/j.rbmo.2014.02.009.
  29. Broekmans FJ, Kwee J, Hendriks DJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685-718. https://doi.org/10.1093/humupd/dml034.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. ROC curve for clinical pregnancy rate for cut-off of serum estradiol/testosterone ratio

Download (106KB)

Copyright (c) 2020 Merkulova A.I., Dzhemlikhanova L.K., Niauri D.A., Gzgzyan A.M., Kogan I.Y., Krikheli I.O., Tapilskaya N.I., Tkachenko N.N., Mekina I.D., Lesik E.A., Komarova E.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies